RU96119964A

RU96119964A - NAFTYLAMIDES AS MEANS OF IMPACT ON THE CENTRAL NERVOUS SYSTEM

Info

Publication number: RU96119964A
Application number: RU96119964/04A
Authority: RU
Inventors: Анн Глейз Шелли; Росс Кестен Зузен; Дэвид Вайз Лауренс; Врайт Джонетен
Original assignee: Варнер-Ламберт Компани
Priority date: 1994-03-24
Filing date: 1995-02-16
Publication date: 1999-02-20

Claims

1. The compound of formula I

in which R and R ^{1 are the} same or different and separately mean hydrogen, alkyl, alkoxy, thioalkoxy, hydroxyl, amino, alkylamino or dialkylamino;
R ² is halogen, nitro, cyano, SO ₂ NH-, alkyl or alkoxy;
R ³ is hydrogen, hydroxy or methoxy;
R ⁴ is hydrogen or alkyl;
R ⁵ is aryl, 2-, 3- or 4-pyridinyl, unsubstituted or substituted by halogen, 2-benzothiazolyl, 2-benzoxazolyl, 3-benzo [b] thienyl, 7-benzo [b] furanyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl or 1-benzisothiazolyl,
or a pharmaceutically acceptable acid addition salt thereof.

2. The compound according to claim 1, in which R ^{2 is a} halogen, nitro group or cyano group, and R ⁴ is methyl or ethyl.

3. The compound according to claim 1, which is 4-bromo-N- {2- [4- (2,3-dichlorophenyl) -1-piperazinyl] ethyl} -1-methoxy-2-naphthalenecarboxamide; 4-bromo-1-methoxy-N- [2- (4-phenyl-1-piperazinyl) ethyl] -2-naphthalenecarboxamide; 4-bromo-1-methoxy-N- [2- (4-pyridin-2-yl-1-piperazinyl) ethyl] -2-naphthalenecarboxamide; 4-bromo-1-methoxy-N- {2- [4- (2-methoxyphenyl) -1-piperazinyl] ethyl} -2-naphthalenecarboxamide; 4-bromo-1-methoxy-N- {2- [4- (2-propylsulfanyl-phenyl) -1-piperazinyl] ethyl} -2-naphthalenecarboxamide; 4-bromo-1-methoxy-N- [2- (4-o-tolyl-1-piperazinyl) ethyl} -2-naphthalenecarboxamide; 4-bromo-N- {2- [4- (2,3-dimethylphenyl-1-piperazinyl] ethyl} -1-methoxy-2-naphthalenecarboxamide; 4-bromo-N- {2- [4- (2-chlorophenyl A) -1-piperazinyl] ethyl} -1-methoxy-2-naphthalenecarboxamide; 4-bromo-N- {2- [4- (3-chlorophenyl) -1-piperazinyl] ethyl} -1-methoxy-2-naphthalenecarboxamide; 4-bromo-N- {2- [4- (4-chlorophenyl) -1-piperazinyl] ethyl} -1-methoxy-2-naphthalenecarboxamide; 4-bromo-N- {2- [4- (3-chloro 2-methylphenyl) -1-piperazinyl] ethyl} -1-methoxy-2-naphthalenecarboxamide; 4-bromo-1-ethoxy-N- {2- [4- (2-methoxyphenyl-1-piperazinyl] ethyl} -2- naphthalenecarboxamide; 4-bromo-1-ethoxy-N- [2- (4-pyridin-2-yl-1-piperazinyl) ethyl] -2-naphthalenecarboxamide; 4-cyano-1-me tox-N- [2- (4-phenyl-1-piperazinyl) ethyl] -2-naphthalenecarboxamide; N- {2- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] ethyl} - 4-bromo-1-methoxy-2-naphthalenecarboxamide; N- {2- [4- (7-benzofuranyl) -1-piperazinyl] ethyl} -4-bromo-1-methoxy-2-naphthalenecarboxamide; and N- [2 - (4-benzo [b] thiophen-3-yl-1-piperazinyl] ethyl} -4-bromo-1-methoxy-2-naphthalenecarboxamide.

4. A method of treating psychoses, psychotic depression, substance abuse and an obsessive state, comprising giving a patient with the indicated diseases a therapeutically effective amount of a compound according to claim 1 in the form of a suitable preparation.

5. A method of treating schizophrenia, comprising giving a patient with the indicated disease a therapeutically effective amount of a compound according to claim 1 in the form of a suitable preparation.

6. Pharmaceutical composition for giving as part of treatment for schizophrenia, containing a therapeutically effective amount of a compound according to claim 1 as a mixture with a pharmaceutically acceptable diluent or carrier.

7. The method of obtaining the compounds of formula I

in which R and R ^{1 are the} same or different and separately mean hydrogen, alkyl, alkoxy, thioalkoxy, hydroxyl, amino, alkylamino or dialkylamino;
R ² is halogen, nitro, cyano, SO ₂ NH-, alkyl or alkoxy;
R ³ is hydrogen, hydroxy or methoxy;
R ⁴ is hydrogen or alkyl;
R ⁵ is aryl, 2-, 3- or 4-pyridinyl, unsubstituted or substituted by halogen, 2-benzothiazolyl, 2-benzoxazolyl, 3-benzo [b] thienyl, 7-benzo [b] furanyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 2-, 3-, 4-, 5-, 6- or 7- or 8-quinolinyl or 1-benzisothiazolyl,
or its pharmaceutically acceptable acid additive salt, including the interaction of the compounds of formula II

in which R, R ¹ , R ² , R ³ and R ⁴ have the indicated meanings,
with a compound of formula III

in which R ⁵ has the indicated meanings,
in the presence of a binding agent in a solvent environment, if necessary, followed by transformation of the obtained formula I into the corresponding acid addition salt by a known method and, if necessary, the acid addition salt obtained by a known method into the compound of formula I.